The last few years have seen a marked increase in the use of glucagon-like peptide-1 receptor agonists (GLP-1 agonists) used for managing type 2 diabetes and as a way to lose weight
These medications mimic what your natural GLP-1 hormone does: boosting insulin secretion, delaying gastric emptying (i.e., slowing digestion), decreasing the release of glucagon (another hormone that controls blood glucose), and increasing satiety
All formulations are prescribed after medical evaluation and administered intramuscularly or dispensed through a licensed pharmacy
Semaglutide and tirzepatide are not currently classified as controlled substances, so DEA registration is not required specifically for those drugs
BMJ 379:e071050 Petschner P, Gonda X, Baksa D, Eszlari N, Trivaks M, Juhasz G, Bagdy G (2018) Genes linking mitochondrial function, cognitive impairment and depression are associated with endophenotypes serving precision medicine